Wikisage, the free encyclopedia of the second generation, is digital heritage

Rufinamide

From Wikisage
Revision as of 20:41, 20 March 2023 by Penarc (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Lennox-Gastaut is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconclusive. Otsuka et al. (2014) state rufinamide as an efficacious and well tolerated AED [1](cf. Alssad et Coren 2014) [2]

"Rufinamide received the status of orphan drug for epilepsy in 2004 in Europe" [3]

It is an inductor of CYP 450

Weblinks

FLexikon:Rufinamid

Pharmawiki:Rufinamid

ATC

https://www.whocc.no/atc_ddd_index/?code=N03AF03

References

References:
  1. ↑ Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan
  2. ↑ Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials
  3. ↑ Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience

Q408565 at Wikidata  Interwiki via Wikidata

Retrieved from "https://en.wikisage.org/w/index.php?title=Rufinamide&oldid=11317"